You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cisplatin

Showing 51 - 75 of 5,020
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Toripalimab (anti-programmed death-1 inhibitor)
  • +4 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Head Neck Cancer Trial in United States (Xevinapan, Cisplatin, External beam)

Recruiting
  • Head and Neck Cancer
  • Basking Ridge, New Jersey
  • +6 more
Nov 17, 2023

Bladder Cancer Trial in Chapel Hill, Durham (pembrolizumab, gemcitabine and cisplatin)

Active, not recruiting
Has Results
  • Bladder Cancer
  • pembrolizumab, gemcitabine and cisplatin
  • Chapel Hill, North Carolina
  • +1 more
Oct 11, 2022

Oral Squamous Cell Carcinoma Trial (Tislelizumab, Albumin paclitaxel, Cisplatin)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • (no location specified)
May 7, 2023

Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)

Active, not recruiting
  • Biliary Tract Neoplasms
  • +2 more
  • Seoul, Korea, Republic of
    Asan Medical Center
Jan 30, 2023

Nasopharyngeal Cancer Trial in Singapore (cisplatin and gemcitabine, induction chemo cisplatin, gemcitabine, bevacizumab and

Not yet recruiting
  • Nasopharyngeal Cancer
  • cisplatin and gemcitabine
  • induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.
  • Singapore, Singapore
    National University Hospital
Mar 22, 2022

Hearing Loss Ototoxic Trial (SENS-401 (R-Azasetron Besylate))

Not yet recruiting
  • Hearing Loss Ototoxic
  • SENS-401 (R-Azasetron Besylate)
  • (no location specified)
Nov 16, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • IMRT and concurrent cisplatin
  • gemcitabine and cisplatin (Induction chemotherapy)
  • Guangzhou, Guangdong, China
  • +3 more
Jul 30, 2023

Adrenocortical Carcinoma Trial in Brescia (Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG,

Recruiting
  • Adrenocortical Carcinoma
  • Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
  • Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
  • Brescia, Italy
    Alfredo Berruti
Jun 12, 2023

Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (gemcitabine and cisplatin,

Recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • gemcitabine and cisplatin
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 4, 2022

Prostate Cancer Trial in Rochester (Cisplatin)

Recruiting
  • Prostate Cancer
  • Cisplatin
  • Rochester, New York
    Wilmot Cancer Institute
Jun 7, 2022

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in

Not yet recruiting
  • Locally Advanced Cholangiocarcinoma
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
      CHA Bundang Medical Center
    Jan 24, 2023

    Head and Neck Squamous Cell Carcinoma Trial in Pittsburgh (Pembrolizumab, Cisplatin, IMRT)

    Active, not recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Sep 15, 2022

    HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

    Recruiting
    • HER2-negative Breast Cancer
    • +5 more
    • Camrelizumab with vinorelbine and cisplatin
    • Beijing, Beijing, China
      Peking University First Hospital
    Oct 15, 2022

    Advanced Malignant Solid Tumors Trial in Changchun (Cisplatin micelle injection (HA132))

    Not yet recruiting
    • Advanced Malignant Solid Tumors
    • Cisplatin micelle injection (HA132)
    • Changchun, Jilin, China
      Jilin Cancer Hospital
    Jul 28, 2022

    Pleural Mesothelioma Trial in Italy (Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab)

    Not yet recruiting
    • Pleural Mesothelioma
    • Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
    • Rozzano, MI, Italy
    • +5 more
    Nov 30, 2023

    Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • Recurrent or Metastatic
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Mar 23, 2022

    Squamous Cell Carcinoma of the Head and Neck Trial in Strasbourg (Split Cisplatin, Cisplatin, Radiotherapy)

    Completed
    • Squamous Cell Carcinoma of the Head and Neck
    • Split Cisplatin
    • +2 more
    • Strasbourg, France
      Centre Paul Strauss
    Mar 10, 2022

    Head Neck Cancer Trial in London, Wales (Olaparib, Cisplatin, IMRT)

    Active, not recruiting
    • Head and Neck Cancer
    • London, United Kingdom
    • +2 more
    Nov 1, 2022

    Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)

    Not yet recruiting
    • Melanoma
    • tunlametinib
    • paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Aug 15, 2023

    Triple Negative Breast Cancer Trial in Shanghai (Gemcitabine, Cisplatin)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • Shanghai, Shanghai, China
      Cancer Hospital/ Institute, Fudan University
    Jul 19, 2022

    Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

    Not yet recruiting
    • Large Cell Lymphoma, Diffuse
    • +2 more
    • AutoSCT
    • +2 more
    • (no location specified)
    May 10, 2023

    Endothelial Function in Germ Cell Tumor Patients Treated With

    Active, not recruiting
    • Germ Cell Cancer
    • Endo-PAT2000 testing
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Nov 7, 2022

    Locally Advanced Head and Neck Squamous Cell Carcinoma Trial in Hamilton, London, Toronto (High-Dose Cisplatin, Low-Dose

    Recruiting
    • Locally Advanced Head and Neck Squamous Cell Carcinoma
    • High-Dose Cisplatin
    • +2 more
    • Hamilton, Ontario, Canada
    • +2 more
    Jun 7, 2022